CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Kamada Ltd. (KMDA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Kamada Ltd. (KMDA)

Pharmaceutical Preparations · market cap $504M · as of 2026-07-08

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
12
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Kamada Ltd. (KMDA) is an Israeli plasma-derived biopharmaceutical company with 6 FDA-approved products distributed across 30+ international markets and a deep pipeline centered on Alpha-1 Antitrypsin (AAT) across multiple indications. At a $415M market cap with 450 employees, the company is a focused specialty plasma player with the nearest binary event being Q3 2026 earnings on August 12. Analyst consensus price targets range $11–$15 against a current price of ~$7.49, implying meaningful upside if pipeline milestones convert.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
Alpha 1-AntitrypsinPhase 3Alpha 1-Antitrypsin Deficiency
KamRAB - HRIGPhase 3Rabies
GLASSIA® and Institution standard of care (SOC)Phase 2Transplantation, Lung Rejection
Kamada-AAT for InhalationPhase 2Alpha-1 Antitrypsin Deficiency
Alpha-1 AntitrypsinPhase 2New Onset Type-1 Diabetes
Aerosolized, human, plasma-derived Alpha-1 AntitrypsinPhase 2Cystic Fibrosis
Active rabies vaccine (US-FDA approved)Phase 3Rabies
Alpha-1 Antitrypsin (AAT, Glassia®)Phase 2Type 1 Diabetes Mellitus
Kamada Anti-SARS-CoV-2Phase 2Covid19
Kamada AAT for inhalationPhase 3Emphysema
Kamada-APIPhase 3Alpha 1-Antitrypsin Deficiency
AAT(Alpha 1 Antitrypsin)Phase 2Type 1 Diabetes
Price & technical context
3-month
+4.3%
6-month
+4.9%
12-month
+11.1%
52-wk range
$6.68–$9.31
vs 50-day MA
+0.5%
vs 200-day MA
+1.2%
Realized vol
36.3%
Max drawdown
-30.9%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for KMDA (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 12 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.